Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...

Cambridge, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing ...

Keep an eye on the first patient dosed in phase 1 and 2 trials of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD),with ...

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company at the forefront of precision genetic medicines with a market capitalization of $1.87 billion, is navigating a critical juncture in its ...

Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin ... M-ATT levels were below the limit of detection ...

Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.

In a report released today, Julian Harrison from BTIG reiterated a Buy rating on Mereo Biopharma Group Plc (MREO – Research Report), with a ...

Scientists mapped the serum proteome longitudinally to uncover biomarkers linked to healthy aging and cardiometabolic ...

A slew of pharma mergers and acquisitions in the first month of 2024 has continued with a $2.2 billion play by Sanofi for Inhibrx and its clinical-stage drug candidate for alpha-1 antitrypsin ...

Entering 2025 having demonstrated rapid translation of genetic insights to positive clinical data; advancing clinically validated and multi-modal ...

Every investor has heard the phrase "buy low, sell high." It's a simple enough piece of advice ... an investigational therapy for Alpha-1 antitrypsin deficiency. And since Oct. 15, 2020, Vertex's ...

Every investor has heard the phrase "buy low, sell high." It's a simple enough piece ... an investigational therapy for Alpha-1 antitrypsin deficiency. And since Oct. 15, 2020, Vertex's shares ...